Descripción de la empresa
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company within the United States market, specifically focusing on the commercialization of prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names through a strategic license agreement with Mayne Pharma for the IMVEXXY, BIJUVA, and ANNOVERA product lines. The firm is situated in the Healthcare sector, functioning within the Drug Manufacturers - Specialty & Generic industry, which implies a business model reliant on licensing intellectual property rather than manufacturing goods or conducting extensive drug development. As of the latest available data, the company possesses a market capitalization of $23.38M and generates annual revenue of $3.02M, while the specific count of employees is not disclosed in current filings. These financial figures indicate a micro-cap entity that occupies a niche position in the market, deriving its scale primarily from the performance of licensed agreements rather than organic expansion or a large workforce. The modest market capitalization relative to the revenue generated suggests a capital-light operational structure typical of royalty-based business models, where value is concentrated in the underlying asset portfolio rather than physical infrastructure or human capital intensity.
Salud financiera
The company reported a revenue of $3.02M over the trailing twelve months, yet recorded a net income of -$653,000 and an EBITDA of -$1,983,000, revealing a significant structural gap where operating expenses substantially exceed gross profitability. This discrepancy between revenue and net income indicates that the cost structure is heavily weighted towards period costs, likely including research, development, or administrative overheads that are not directly tied to the cost of goods sold. Despite the negative net income and EBITDA, the firm maintains a free cash flow of $303,625, which provides a degree of financial flexibility by allowing the company to cover essential operational obligations and potentially fund growth initiatives without immediate external financing. The gross margin stands at an impressive 100.0%, reflecting the royalty-based nature of the business where the cost of goods sold is negligible compared to sales, whereas the operating margin of -108.5% and profit margin of -18.8% highlight the burden of fixed costs and general and administrative expenses consuming the entire operating surplus. On the liability side, the company holds $7.48M in cash against $6.10M in debt, resulting in a debt-to-equity ratio of 22.69, which technically suggests a leveraged balance sheet due to the mathematical inversion often seen in loss-making entities, though the absolute debt load is manageable given the cash reserves. The current ratio is recorded at 3.02, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, ensuring the ability to meet immediate obligations. Furthermore, the return on equity is -2.4% and the return on assets is -3.9%, metrics that reveal that management has not yet generated positive returns on the capital deployed, reflecting the early-stage or transitional phase of the company's profitability trajectory.
Evaluación de valoración
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is calculated at 5.77, implying that the market prices in an expectation of future earnings normalization or growth. The price-to-book ratio is 0.87, indicating that the market values the company at approximately 13% below its book value, which often suggests a discount applied to speculative assets or a lack of consistent profitability history. Alternative valuation measures such as the price-to-sales ratio of 7.74 and an EV/EBITDA of -11.09 suggest that investors are pricing the stock based on revenue generation and growth potential rather than current earnings power, given the negative earnings multiple. The stock has traded between a 52-week high of $2.95 and a 52-week low of $0.84, meaning the current trading price sits within a range that reflects significant volatility and potential undervaluation relative to the recent peak. The beta value of 0.56 indicates that the stock exhibits lower volatility relative to the broader market, moving less than half as much as the market index in response to general economic shifts. These valuation characteristics collectively suggest that the market is compensating for the high risk associated with negative earnings and limited historical returns, while acknowledging the potential for earnings recovery driven by the underlying royalty agreements.
Growth & Income
The revenue growth year-over-year is reported at 33.9%, demonstrating strong top-line expansion, whereas the earnings growth is N/A due to the absence of positive earnings in the current period, implying that revenue growth is currently outpacing earnings growth as the company works to achieve profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all available cash flow to reinvest into business operations, licensing agreements, or debt reduction rather than distributing income to shareholders. This reinvestment strategy is consistent with the growth phase of a micro-cap pharmaceutical royalty company that prioritizes scaling the licensed portfolio over providing immediate income to investors. The overall growth and income profile is characterized by robust revenue expansion and a zero-dividend policy that channels capital back into the business, though the lack of earnings growth metrics currently limits the ability to assess profitability trajectory.